# Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

> **NCT05841095** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 24 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** ISA104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05841095
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-04
- **Primary completion:** 2024-09-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841095, "Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05841095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*